Protalix BioTherapeutics (AMEX:PLX) Stock Quotes, Forecast and News Summary

Q: What sector and industry does Protalix BioTherapeutics (PLX) operate in?

Protalix BioTherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.

Protalix BioTherapeutics Stock (AMEX: PLX) stock price, news, charts, stock research, profile.

Open	-
Close	-
Volume / Avg.	48.00 / 174.70K
Day Range	- - -
52 Wk Range	0.82 - 1.90
Market Cap	$99.28M
P/E Ratio	-
Dividend Yield	-
Exchange	AMEX
RSI	67
Short Interest	4.41%
Days to Cover	21.68

Recent News

Protalix BioTherapeutics And 2 Other Penny Stocks Insiders Are Buying

The Dow Jones closed lower by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Lisa Levin

Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics

The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult

Vandana Singh

Protalix Clocks 40% Decline In Q1 Revenues Reflecting Lower Sales To Brazil

Nabaparna Bhattacharya

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	-
Close	-
Volume / Avg.	48.00 / 174.70K
Day Range	- - -
52 Wk Range	0.82 - 1.90
Market Cap	$99.28M
P/E Ratio	-
Dividend Yield	-
Exchange	AMEX
RSI	67
Short Interest	4.41%
Days to Cover	21.68

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Protalix BioTherapeutics (PLX) stock?

You can purchase shares of Protalix BioTherapeutics (AMEX:PLX) through any online brokerage.

View our list of the best stock brokerages

Who are Protalix BioTherapeutics (PLX) competitors?

Other companies in Protalix BioTherapeutics’s space includes: Renovaro (NASDAQ:RENB), Cellectar Biosciences (NASDAQ:CLRB), Armata Pharmaceuticals (AMEX:ARMP), Citius Oncology (NASDAQ:CTOR) and Adicet Bio (NASDAQ:ACET).

What is the forecast, or price target, for Protalix BioTherapeutics (PLX) stock?

Protalix BioTherapeutics has a consensus price target of $10.00.

What is the current price for Protalix BioTherapeutics (PLX)?

The stock price for Protalix BioTherapeutics (AMEX: PLX) is $1.3499 last updated November 12, 2024 at 7:59 PM EST.

Does Protalix BioTherapeutics (PLX) pay a dividend?

There are no upcoming dividends for Protalix BioTherapeutics.

When is Protalix BioTherapeutics (AMEX:PLX) reporting earnings?

Protalix BioTherapeutics’s Q3 earnings are confirmed for Thursday, November 14, 2024.

Is Protalix BioTherapeutics (PLX) going to split?

There is no upcoming split for Protalix BioTherapeutics.

What sector and industry does Protalix BioTherapeutics (PLX) operate in?

Protalix BioTherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.

Comments

Protalix BioTherapeutics

Protalix BioTherapeutics (PLX) Forecast